December 2016

Recursion wins award for drug discovery platform

Monday, December 26, 2016

Recursion Pharmaceuticals announced that it has won two Fierce Innovation awards from the biotech and pharmaceutical industries today for its innovative platform. The awards, “Best Biotech Innovation” and “Best In Show—New Product or Service,” recognize Recursion’s disruptive combination of experimental biology and artificial intelligence applied to drug discovery.

[Read More]

FDA accepts for review sNDA for Pfizer’s IBRANCE metastatic breast cancer

Friday, December 23, 2016

Pfizer has announced that the FDA accepted for review a supplemental New Drug Application (sNDA) for its first-in-class CDK 4/6 inhibitor, IBRANCE (palbociclib). The sNDA supports the conversion of the accelerated approval of IBRANCE in combination with letrozole to regular approval and includes data from the phase III PALOMA-2 trial, which evaluated IBRANCE as initial therapy in combination with letrozole for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. This is the same patient population as the randomized phase II PALOMA-1 trial upon which the accelerated approval of IBRANCE plus letrozole was granted in February 2015. 

[Read More]

TPG Capital to acquire Mediware Information Systems

Friday, December 23, 2016

Mediware Information Systems, a in software for healthcare and human services providers, has announced that TPG Capital, the global private equity fund of alternative asset firm TPG, has entered into a definitive agreement to acquire the company from private equity firm Thoma Bravo. The transaction is expected to close during the first quarter of 2017 and is subject to customary closing conditions. Additional terms of the transaction were not disclosed.

[Read More]

Helomics completes restructuring into fully-integrated CRO

Thursday, December 22, 2016

Helomics, a privately held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic and biotech industries, has announced the completion of the final phase of its corporate realignment toward becoming a fully-integrated clinical contract research and clinical products organization (ICCRO).  

[Read More]

Study: CRO turnover remains high

Thursday, December 22, 2016

Turnover in the U.S. for clinical monitoring jobs (the function that monitors participants’ health during a clinical trial) at CROs remained high at 25.1% in 2015, almost the same as the previous year’s reported 25.4% (2014). Turnover remained high despite the 7% spike in average salaries for professional positions from 2014 to 2015, according to the 18th annual CRO Industry Global Compensation and Turnover Survey, conducted by HR+Survey Solutions, a specialty compensation consulting and research firm.

[Read More]

Bracket add Lewis Fredane as clinical vice president

Wednesday, December 21, 2016

Bracket, a clinical trial technology and specialty services provider, announced the addition of Clinical Vice President Lewis M. Fredane, M.D., to its global team. A board certified neurologist with more than 30 years of clinical research experience, Fredane brings a strategic combination of clinical and industry research expertise to his new role.

[Read More]

HHS appoints Quorum’s Dr. Stephen Rosenfeld SACHRP Chair

Wednesday, December 21, 2016

Dr. Stephen J. Rosenfeld, executive IRB chair for Quorum Review IRB, has accepted an invitation from Sylvia Burwell, the Secretary of the Department of Health and Human Services (DHHS), to chair the Secretary’s Advisory Committee for Human Research Protections (SACHRP). SACHRP comprises experts in the fields of research and ethics, and provides advice and recommendations to the Secretary of DHHS on issues pertaining to the protection of human subjects in research.

[Read More]

Symcel and Colzyx partner

Tuesday, December 20, 2016

Symcel, the company behind the cell-based assay tool for real-time cellular bioenergetic measurements, calScreener, has partnered with Colzyx to test 25 different new collagen VI derived antimicrobial peptides—analyzing their capability to kill bacterial growth. These newly discovered, first-in-kind peptides each have the capability to kill bacteria in different ways. The technology will be used flexibly to test each peptide independently or in combination with others.   

[Read More]